Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8234 results

  1. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Kidney Cancer

    In development Reference number: GID-NG10398 Expected publication date:  19 March 2026

    NICE guideline
    In development

  3. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

    NICE guideline
    In development

  4. Deuruxolitinib for treating severe alopecia areata ID6597

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  5. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    In development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    Awaiting development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  11. Invoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

    Diagnostics guidance
    In development

  15. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date: TBC

    Technology appraisal guidance
    In development